Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size Study, by Type, by Therapy, by Population Type, by Drug Type, by Route of Administration, by End User, by Distribution Channel, and Regional Forecasts 2022-2032

Description

The Global Chemotherapy-induced Nausea and Vomiting (CINV) Drugs Market, valued at approximately USD 1.9 billion in 2023, is poised to grow at a compound annual growth rate (CAGR) of 6.60% during the forecast period from 2024 to 2032. This critical market addresses the distressing side effects associated with chemotherapy, offering therapeutic solutions to improve patients' quality of life. The drugs in this segment cater to various types of emesis-acute, delayed, anticipatory, and refractory-through a mix of targeted therapies such as NK-1 receptor antagonists and serotonin receptor antagonists. These advancements, supported by increasing investment in oncology research and rising awareness of supportive care measures, are driving market growth.

The increasing prevalence of cancer worldwide is a primary catalyst for market expansion, creating an urgent demand for effective CINV management solutions. Pharmaceutical companies are innovating novel drug formulations to provide long-lasting relief with minimal side effects. Furthermore, the adoption of oral and parenteral administration routes ensures tailored treatment approaches for diverse patient needs. While the high cost of branded medications and regulatory challenges may pose hurdles, the entry of generic drugs and ongoing government support for cancer care initiatives are expected to counterbalance these barriers, fostering market development.

The geographical landscape showcases significant variations in market dynamics. North America remains a dominant player, attributed to a well-established healthcare infrastructure, high adoption rates of advanced therapies, and substantial investment in oncology drug research. Europe follows closely, supported by robust public health initiatives and a focus on improving cancer treatment outcomes. Meanwhile, the Asia-Pacific region exhibits the fastest growth trajectory, driven by a burgeoning patient population, increased healthcare spending, and rising awareness of chemotherapy-induced side effects. Countries like China, India, and Japan are at the forefront, offering lucrative opportunities for market players to expand their footprint.

Innovations in drug delivery mechanisms and the development of combination therapies are reshaping the CINV drugs market. Pharmaceutical companies are increasingly leveraging advanced technologies to enhance drug efficacy and patient compliance. Moreover, partnerships between research institutes, healthcare providers, and pharmaceutical firms are fueling innovation and ensuring accessibility to cutting-edge treatments. As the global healthcare landscape evolves, the CINV drugs market is set to play a pivotal role in mitigating the adverse effects of chemotherapy, contributing to improved cancer care outcomes.

Major market players included in this report are:

Merck & Co., Inc.
Novartis International AG
Helsinn Healthcare SA
Heron Therapeutics, Inc.
Dr. Reddy's Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Baxter International Inc.
Acacia Pharma Group plc
Eisai Co., Ltd.
Fresenius Kabi AG
Sanofi S.A.
Mylan N.V.
Bristol Myers Squibb
Pfizer Inc.

The detailed segments and sub-segment of the market are explained below:

By Type:

Acute Emesis
Delayed Emesis
Anticipatory Emesis
Refractory Emesis

By Therapy:

NK-1 Receptor Antagonist
Serotonin Receptor Antagonist
Others

By Population Type:

Children
Adults

By Drug Type:

Branded
Generics

By Route of Administration:

Oral
Parenteral

By End User:

Hospitals
Specialty Clinics
Home Healthcare
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others

By Region:

North America:

U.S.
Canada

Europe:

UK
Germany
France
Spain
Italy
Rest of Europe

Asia-Pacific:

China
India
Japan
Australia
South Korea
Rest of Asia-Pacific

Latin America:

Brazil
Mexico
Rest of Latin America

Middle East & Africa:

Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year - 2022
Base Year - 2023
Forecast Period - 2024 to 2032

Key Takeaways:

Detailed market estimates and forecasts from 2022 to 2032.
Comprehensive regional analysis, including country-level insights.
Thorough segmentation covering type, therapy, population type, drug type, route of administration, end user, and distribution channels.
Competitive landscape profiling leading market players and their strategies.
Actionable insights for stakeholders to capitalize on emerging trends and growth opportunities.

Chapter 1. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Executive Summary

1.1. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Therapy
- 1.3.3. By Population Type
- 1.3.4. By Drug Type
- 1.3.5. By Route of Administration
- 1.3.6. By End User
- 1.3.7. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Prevalence of Cancer Worldwide
- 3.1.2. Rising Investment in Oncology Research
- 3.1.3. Growing Awareness of Supportive Care Measures
3.2. Market Challenges
- 3.2.1. High Cost of Branded Medications
- 3.2.2. Regulatory Challenges
3.3. Market Opportunities
- 3.3.1. Entry of Generic Drugs
- 3.3.2. Ongoing Government Support for Cancer Care Initiatives
- 3.3.3. Innovations in Drug Delivery Mechanisms

Chapter 4. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by Type 2022-2032

5.1. Segment Dashboard
5.2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Acute Emesis
- 5.2.2. Delayed Emesis
- 5.2.3. Anticipatory Emesis
- 5.2.4. Refractory Emesis

Chapter 6. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by Therapy 2022-2032

6.1. Segment Dashboard
6.2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. NK-1 Receptor Antagonist
- 6.2.2. Serotonin Receptor Antagonist
- 6.2.3. Others

Chapter 7. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by Population Type 2022-2032

7.1. Segment Dashboard
7.2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Population Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.2.1. Children
- 7.2.2. Adults

Chapter 8. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by Drug Type 2022-2032

8.1. Segment Dashboard
8.2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.2.1. Branded
- 8.2.2. Generics

Chapter 9. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by Route of Administration 2022-2032

9.1. Segment Dashboard
9.2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 9.2.1. Oral
- 9.2.2. Parenteral

Chapter 10. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by End User 2022-2032

10.1. Segment Dashboard
10.2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 10.2.1. Hospitals
- 10.2.2. Specialty Clinics
- 10.2.3. Home Healthcare
- 10.2.4. Others

Chapter 11. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by Distribution Channel 2022-2032

11.1. Segment Dashboard
11.2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 11.2.1. Hospital Pharmacy
- 11.2.2. Retail Pharmacy
- 11.2.3. Online Pharmacies
- 11.2.4. Others

Chapter 12. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size & Forecasts by Region 2022-2032

12.1. North America Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.1.1. U.S. Chemotherapy-induced Nausea and Vomiting Drugs Market
  - 12.1.1.1. Type Breakdown Size & Forecasts, 2022-2032
  - 12.1.1.2. Therapy Breakdown Size & Forecasts, 2022-2032
- 12.1.2. Canada Chemotherapy-induced Nausea and Vomiting Drugs Market
12.2. Europe Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.2.1. UK Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.2.2. Germany Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.2.3. France Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.2.4. Spain Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.2.5. Italy Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.2.6. Rest of Europe Chemotherapy-induced Nausea and Vomiting Drugs Market
12.3. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.3.1. China Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.3.2. India Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.3.3. Japan Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.3.4. Australia Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.3.5. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.3.6. Rest of Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market
12.4. Latin America Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.4.1. Brazil Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.4.2. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.4.3. Rest of Latin America Chemotherapy-induced Nausea and Vomiting Drugs Market
12.5. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.5.1. Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.5.2. South Africa Chemotherapy-induced Nausea and Vomiting Drugs Market
- 12.5.3. Rest of Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Market

Chapter 13. Competitive Intelligence

13.1. Key Company SWOT Analysis
- 13.1.1. Merck & Co., Inc.
- 13.1.2. Novartis International AG
- 13.1.3. Helsinn Healthcare SA
13.2. Top Market Strategies
13.3. Company Profiles
- 13.3.1. Merck & Co., Inc.
  - 13.3.1.1. Key Information
  - 13.3.1.2. Overview
  - 13.3.1.3. Financial (Subject to Data Availability)
  - 13.3.1.4. Product Summary
  - 13.3.1.5. Market Strategies
- 13.3.2. Novartis International AG
- 13.3.3. Helsinn Healthcare SA
- 13.3.4. Heron Therapeutics, Inc.
- 13.3.5. Dr. Reddy's Laboratories Ltd.
- 13.3.6. Teva Pharmaceutical Industries Ltd.
- 13.3.7. GlaxoSmithKline plc
- 13.3.8. Baxter International Inc.
- 13.3.9. Acacia Pharma Group plc
- 13.3.10. Eisai Co., Ltd.

Chapter 14. Research Process

14.1. Research Process
- 14.1.1. Data Mining
- 14.1.2. Analysis
- 14.1.3. Market Estimation
- 14.1.4. Validation
- 14.1.5. Publishing
14.2. Research Attributes